CD8A and cancer: Mutation-dense or DNA mismatch repair-deficient cancers such as squamous carcinomas and melanoma typically evoke stronger CD8+ T cell responses to ICI therapy, compared to more genetically stable carcinomas such as pancreatic and urothelial25,26.